Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
Open accessAbstract
Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer, is an attractive therapeutic strategy but the mechanisms governing this process are poorly understood. Blockade of ERK1/2 reactivation following EGFR TKI treatment by combined EGFR/MEK inhibition uncovers cells that survive by entering a senescence-like dormant state characterized by high YAP/TEAD activity. YAP/TEAD engage the epithelial-to-mesenchymal transition transcription factor SLUG to directly repress pro-apoptotic BMF, limiting drug-induced apoptosis. Pharmacological co-inhibition of YAP and TEAD, or genetic deletion of YAP1, all deplete dormant cells by enhancing EGFR/MEK inhibition-induced apoptosis. Enhancing the initial efficacy of targeted therapies could ultimately lead to prolonged treatment responses in cancer patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
YAP/TAZ plays a crucial role in intrinsic and acquired resistance to inhibitors targeting the RTK/MAPK pathway.
“Particularly, YAP/TAZ plays a crucial role in the intrinsic and acquired resistance to inhibitors targeting RTK/MAPK pathway (24, 28–32).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [29]
The Results (pages not provided) show that YAP/TEAD is critical for drug-tolerant dormancy after combined EGFR/MEK inhibition in EGFR-mutant lung cancer cells; another Results passage reports nuclear YAP in tumors with acquired resistance to that combination. The paper does not establish a crucial role for TAZ, or for YAP/TAZ across intrinsic and acquired resistance to RTK/MAPK-targeting inhibitors generally. (LLM, conf=0.85)
Experimental — accuracy not yet measuredDysregulation of the Hippo-YAP/TAZ pathway serves as a central resistance mechanism in multiple therapies, particularly intrinsic and acquired resistance to RTK, RAF, or MEK inhibitors.
“accumulating evidence suggests that the dysregulation of the Hippo-YAP/TAZ pathway serves as a central resistance mechanism in multiple therapies, particularly in the intrinsic and acquired resistance to RTK, RAF, or MEK inhibitors (24, 28, 29).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [29]
The Discussion (page unavailable) identifies YAP activation as the dominant survival mechanism during combined EGFR/MEK inhibition in EGFR-mutant NSCLC, and reports an association with resistance to targeted treatment in several contexts. The Results also find nuclear YAP in tumors with acquired resistance to EGFR/MEK treatment. The paper does not establish Hippo-YAP/TAZ dysregulation as a central mechanism of both intrinsic and acquired resistance across RTK, RAF, and MEK inhibitors. (LLM, conf=0.85)
Experimental — accuracy not yet measuredKurppa et al. observed that after treatment with the combination of EGFR and MEK inhibitors, the vast majority of barcodes were unique, suggesting that the ability of cells to enter dormancy following dual inhibition of EGFR and MEK is predominately driven by a stochastic process.
“the authors observed that after treatment with the combination of EGFR and MEK inhibitors, the vast majority of barcodes were unique, suggesting that the ability of cells to enter dormancy following dual inhibition of EGFR and MEK is predominately driven by a stochastic process [56].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [56]
Kurppa et al. DNA barcoding on PC9 cells treated with EGFR inhibitor alone revealed a large fraction of shared barcodes, consistent with selection of pre-existing persister clones.
“The results revealed a large fraction of shared barcodes within the cells treated with EGFR inhibitor alone, consistent with selection of pre-existing persister clones.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [56]
Other studies suggest that some persister phenotypes arise via plasticity induced by drug treatment.
“Meanwhile, other studies suggest that some persister phenotypes arise via plasticity induced by drug treatment [56,64,65].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [56]
Combined EGFR/MEK inhibition of EGFR-mutant NSCLC model cells selected a population of dormant drug-tolerant cells exhibiting senescence-like features characterized by high YAP/TEAD activity.
“Kurppa et al. observed that combined EGFR/MEK inhibition of EGFR-mutant NSCLC model cells selected a population of dormant drug-tolerant cells exhibiting senescence-like features characterized by high YAP/TEAD activity [56].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607 · see citing works
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386 · see citing works
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807 · see citing works
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382 · see citing works
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174 · see citing works
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063 · see citing works
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908 · see citing works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works
deepTools2: a next generation web server for deep-sequencing data analysis
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., & Manke, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw257 · Cited by 8,096 · see citing works
Scenic: single-cell regulatory network inference and clustering.
Aibar, S., González-Blas, C. B., Moerman, T., Huynh-Thu, V. A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.-C., Geurts, P., Aerts, J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4463 · Cited by 6,520 · see citing works
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979 · see citing works
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · see citing works
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206 · see citing works
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works
Self-citationCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · see citing works
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · see citing works
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379 · see citing works
ATAC-seq: a method for assaying chromatin accessibility genome-wide
Buenrostro, J. D., Wu, B., Chang, H. Y., & Greenleaf, W. J. (2015) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb2129s109 · Cited by 3,289 · see citing works
Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824 · see citing works
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · see citing works
Self-citationEMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539 · see citing works
Alectinib versus Crizotinib in Untreated <i>ALK</i> -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527 · see citing works
TEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498 · see citing works
Self-citationAn improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues
Corces, M. R., Trevino, A. E., Hamilton, E. G., Greenside, P. G., Sinnott-Armstrong, N. A., Vesuna, S., Satpathy, A. T., Rubin, A. J., Montine, K. S., Wu, B., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4396 · Cited by 2,496 · see citing works
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349 · see citing works
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278 · cited 1× · see citing works
“Using immunofluorescence (IF) following a 10 day treatment with OT, we detected a robust increase in punctate, H3K9Me3-positive nuclear foci, another hallmark of senescence (Narita et al., 2003) (Figure 1K).”
BackgroundYAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970 · see citing works
The Biology of YAP/TAZ: Hippo Signaling and Beyond
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00005.2014 · Cited by 1,797 · see citing works
Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J., & Toussaint, O. (2009) · Nature Protocols · doi:10.1038/nprot.2009.191 · Cited by 1,668 · see citing works
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells
Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A. R., Poletti, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.048 · Cited by 1,381 · see citing works
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224 · see citing works
Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185 · see citing works
Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L., & Corn, J. E. (2016) · Nature Biotechnology · doi:10.1038/nbt.3481 · Cited by 1,098 · see citing works
Blanke, C. D., Rankin, C. J., Demetri, G. D., Ryan, C. W., von Mehren, M., Benjamin, R. S., Raymond, A. K., Bramwell, V. H. C., Baker, L. H., Maki, R. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4452 · Cited by 1,074 · see citing works
Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059 · see citing works
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013 · see citing works
Self-citationHata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985 · see citing works
Lei, Q., Zhang, H., Zhao, B., Zha, Z., Bai, F., Pei, X., Zhao, S., Xiong, Y., & Guan, K. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01874-07 · Cited by 925 · see citing works
Therapy-induced senescence in cancer.
Ewald, J. A., Desotelle, J. A., Wilding, G., & Jarrard, D. F. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq364 · Cited by 824 · see citing works
β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis
Rosenbluh, J., Nijhawan, D., Cox, A. G., Li, X., Neal, J. T., Schafer, E. J., Zack, T. I., Wang, X., Tsherniak, A., Schinzel, A. C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.11.026 · Cited by 757 · see citing works
Self-citationKRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744 · see citing works
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716 · cited 2× · see citing works
“Intriguingly, the ability of YAP to compensate for the loss of dominant oncogene in MAPK-dependent cancers has been previously shown in the context of mutant KRAS-driven NSCLC and pancreatic ductal adenocarcinoma (Kapoor et al., 2014; Shao et al., 2014).”
BackgroundSelf-citationDeveloping Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y. A., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 662 · see citing works
Self-citationZhang, H., Liu, C., Zha, Z., Zhao, B., Yao, J., Zhao, S., Xiong, Y., Lei, Q., & Guan, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900843200 · Cited by 572 · see citing works
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551 · see citing works
Zhang, Z., & Marshall, A. G. (1998) · Journal of the American Society for Mass Spectrometry · doi:10.1016/s1044-0305(97)00284-5 · Cited by 511 · see citing works
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507 · see citing works
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
Wang, Y., Xu, X., Maglic, D., Dill, M. T., Mojumdar, K., Ng, P. K.-S., Jeong, K. J., Tsang, Y. H., Moreno, D., Bhavana, V. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.001 · Cited by 500 · cited 1× · see citing works
“The YAP signature was curated from gene sets obtained from multiple studies (Cordenonsi et al., 2011; Dupont et al., 2011; Wang et al., 2018; Zhang et al., 2009, 2008a).”
MethodSelf-citationCosta, D. B., Halmos, B., Kumar, A., Schumer, S., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 499 · see citing works
Bhattacharyya, S., Rainey, M. A., Arya, P., Mohapatra, B. C., Mushtaq, I., Dutta, S., George, M., Storck, M. D., McComb, R. D., Muirhead, D. E., et al. (2017) · Scientific Reports · doi:10.1038/srep42320 · Cited by 459 · see citing works
Weakly supervised learning of biomedical information extraction from curated data
Jain, S., Kashyap, R., Kuo, T.-T., Bhargava, S., Lin, G., & Hsu, C. (2016) · BMC Bioinformatics · doi:10.1186/s12859-015-0844-1 · Cited by 454 · see citing works
Zaidi, S. K., Sullivan, A. J., Medina, R., Ito, Y., van Wijnen, A. J., Stein, J. L., Lian, J. B., & Stein, G. S. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600073 · Cited by 401 · see citing works
Critical pathways in cellular senescence and immortalization revealed by gene expression profiling
Fridman, A. L., & Tainsky, M. A. (2008) · Oncogene · doi:10.1038/onc.2008.213 · Cited by 385 · see citing works
Cragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. S., & Strasser, A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040316 · Cited by 341 · see citing works
Mitochondria—Judges and Executioners of Cell Death Sentences
Bhola, P. D., & Letai, A. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.019 · Cited by 326 · see citing works
Gong, Y., Somwar, R., Politi, K. A., Balak, M. N., Chmielecki, J., Jiang, X., & Pao, W. J. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040294 · Cited by 322 · see citing works
Regulatory phosphorylation of Bim: sorting out the ERK from the JNK
Ley, R., Ewings, K. E., Hadfield, K., & Cook, S. J. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401688 · Cited by 315 · see citing works
Covalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315 · see citing works
Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway
Chan, P., Han, X., Zheng, B., DeRan, M., Yu, J., Jarugumilli, G. K., Deng, H., Pan, D., Luo, X., & Wu, X. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2036 · Cited by 313 · see citing works
ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types
Lehmann, W., Mossmann, D., Kleemann, J., Mock, K., Meisinger, C., Brummer, T., Herr, R., Brabletz, S., Stemmler, M. P., & Brabletz, T. (2016) · Nature Communications · doi:10.1038/ncomms10498 · Cited by 305 · see citing works
Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302 · cited 1× · see citing works
“The expression of several classical SASP factors (Coppé et al., 2008) in the cytokine, chemokine, IGFBP and MMP families was also upregulated in the dormant cells (Figure S3C), analogous to SASP.”
ResultA genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway
Mohseni, M., Sun, J., Lau, A., Curtis, S., Goldsmith, J., Fox, V. L., Wei, C., Frazier, M., Samson, O., Wong, K.-K., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2884 · Cited by 294 · see citing works
Self-citationReactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Ercan, D., Xu, C., Yanagita, M., Monast, C. S., Pratilas, C. A., Montero, J., Butaney, M., Shimamura, T., Sholl, L., Ivanova, E. V., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0103 · Cited by 294 · see citing works
Self-citationBeyer, T. A., Weiss, A., Khomchuk, Y., Huang, K., Ogunjimi, A. A., Varelas, X., & Wrana, J. L. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.021 · Cited by 293 · see citing works
Transcriptional Co-repressor Function of the Hippo Pathway Transducers YAP and TAZ
Kim, M., Kim, T., Johnson, R. L., & Lim, D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.015 · Cited by 285 · see citing works
Guler, G. D., Tindell, C. A., Pitti, R., Wilson, C., Nichols, K., KaiWai Cheung, T., Kim, H.-J., Wongchenko, M., Yan, Y., Haley, B., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.002 · Cited by 277 · see citing works
Noland, C. L., Gierke, S., Schnier, P. D., Murray, J. M., Sandoval, W. N., Sagolla, M. S., Dey, A., Hannoush, R. N., Fairbrother, W. J., & Cunningham, C. N. (2015) · Structure · doi:10.1016/j.str.2015.11.005 · Cited by 268 · see citing works
Evaluation and comparison of bioinformatic tools for the enrichment analysis of metabolomics data
Marco‐Ramell, A., Palau‐Rodriguez, M., Alay, A., Tulipani, S., Urpí-Sardà, M., Sánchez‐Pla, Á., & Andrés‐Lacueva, C. (2018) · BMC Bioinformatics · doi:10.1186/s12859-017-2006-0 · Cited by 261 · see citing works
Zhang, J., Smolen, G. A., & Haber, D. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6205 · Cited by 243 · see citing works
Starcode: sequence clustering based on all-pairs search
Zorita, E. V., Cuscó, P., & Filion, G. J. P. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv053 · Cited by 241 · see citing works
Pobbati, A. V., Han, X. Y., Hung, A. W., Seetoh, W.-G., Huda, N., Chen, G.-Y., Kang, C., Chia, C. S. B., Luo, X., Hong, W., et al. (2015) · Structure · doi:10.1016/j.str.2015.09.009 · Cited by 212 · see citing works
Tang, Y., Feinberg, T. Y., Keller, E. T., Li, X.-Y., & Weiss, S. J. (2016) · Nature Cell Biology · doi:10.1038/ncb3394 · Cited by 212 · see citing works
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
CHAIB-OUKADOUR, I., Karachaliou, N., Pilotto, S., Servat, J. C., Cai, X., Li, X., Drozdowskyj, A., Codony, C., Yang, J. E., Hu, C., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx014 · Cited by 210 · see citing works
Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins
Wang, W., Li, N., Li, X., Tran, M. K., Han, X., & Chen, J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.014 · Cited by 208 · see citing works
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR -Mutant Lung Cancer
Tricker, E. M., Xu, C., Uddin, S., Capelletti, M., Ercan, D., Ogino, A., Pratilas, C. A., Rosen, N. X., Gray, N. S., Wong, K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0063 · Cited by 207 · see citing works
Self-citationCornwell, M., Vangala, M., Taing, L., Herbert, Z. T., Köster, J., Li, B., Sun, H., Li, T., Zhang, J., Qiu, X., et al. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2139-9 · Cited by 203 · see citing works
Self-citationBum‐Erdene, K., Zhou, D., González-Gutiérrez, G., Ghozayel, M. K., Si, Y., Xu, D. D., Shannon, H. E., Bailey, B. J., Corson, T. W., Pollok, K. E., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.11.010 · Cited by 200 · see citing works
Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Bahcall, M., Sim, T., Paweletz, C. P., Patel, J. D., Alden, R. S., Kuang, Y., Sacher, A. G., Kim, N. D., Lydon, C., Awad, M. M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0686 · Cited by 183 · see citing works
Self-citationMolecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
Cortot, A. B., & Jänne, P. A. (2014) · European Respiratory Review · doi:10.1183/09059180.00004614 · Cited by 158 · see citing works
Niehues, S., Bussmann, J., Steffes, G., Erdmann, I., Köhrer, C., Sun, L., Wagner, M., Schäfer, K. J., Wang, G., Koerdt, S. N., et al. (2016) · Nature Communications · doi:10.1038/ncomms10497 · Cited by 146 · see citing works
YAP promotes erlotinib resistance in human non-small cell lung cancer cells
Hsu, P., You, B., Yang, Y., Zhang, W., Wang, Y., Xu, Z., Dai, Y., Liu, S., Yang, C., Li, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10458 · Cited by 119 · see citing works
ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and analysis pipeline
Qin, Q., Mei, S., Wu, Q., Sun, H., Li, L., Taing, L., Chen, S., Li, F., Liu, T., Zang, C., et al. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1274-4 · Cited by 119 · see citing works
Self-citationManagement of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012
Ku, G. Y., Tan, I. B., Yau, T. C. C., Boku, N., Laohavinij, S., Cheng, A., Kang, Y., & Lopes, G. D. L., Jr. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70424-2 · Cited by 76 · see citing works
YAP1 oncogene and its eight isoforms
Sudol, M. (2012) · Oncogene · doi:10.1038/onc.2012.520 · Cited by 49 · see citing works
Alexander, W. M., Ficarro, S. B., Adelmant, G., & Marto, J. A. (2017) · PROTEOMICS · doi:10.1002/pmic.201700091 · Cited by 45 · see citing works
Self-citationFicarro, S. B., Browne, C. M., Card, J. D., Alexander, W. M., Zhang, T., Park, E., McNally, R., Dhe‐Paganon, S., Seo, H., Lamberto, I., et al. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03394 · Cited by 37 · see citing works
Self-citationThress, K. S., Jacobs, V. N., Angell, H. K., Yang, J. C., Sequist, L. V. D., Blackhall, F. H., Su, W., Schüler, M., Wolf, J., Gold, K. A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.011 · Cited by 25 · see citing works
mzStudio: A Dynamic Digital Canvas for User-Driven Interrogation of Mass Spectrometry Data
Ficarro, S. B., Alexander, W., & Marto, J. A. (2017) · Proteomes · doi:10.3390/proteomes5030020 · Cited by 25 · see citing works
Self-citationCloneSifter: enrichment of rare clones from heterogeneous cell populations
Feldman, D., Tsai, F., Garrity, A. J., O’Rourke, R., Brenan, L., Ho, P., Gonzalez, E. M., Konermann, S., Johannessen, C. M., Beroukhim, R., et al. (2020) · BMC Biology · doi:10.1186/s12915-020-00911-3 · Cited by 24 · see citing works
Self-citationRamalingam, S. S., Saka, H., Ahn, M., Yu, H. A., Yu, H. A., Horn, L., Hida, T., Cantarini, M., Verheijen, R. B., Wessen, J., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct034 · Cited by 7 · see citing works
CloneRetriever: retrieval of rare clones from heterogeneous cell populationsPreprint
Feldman, D., Tsai, F., Garrity, A. J., O’Rourke, R., Brenan, L., Ho, P., Gonzalez, E. M., Konermann, S., Johannessen, C. M., Beroukhim, R., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/762708 · Cited by 2 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860 · see citing works
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C. Y., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 850 · see citing works
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503 · see citing works
Persistent Cancer Cells: The Deadly Survivors
Shen, S., Vagner, S., & Robert, C. (2020) · Cell · doi:10.1016/j.cell.2020.10.027 · Cited by 304 · see citing works
Lung cancer in patients who have never smoked — an emerging disease
LoPiccolo, J., Gusev, A., Christiani, D. C., & Janne, P. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00844-0 · Cited by 307 · see citing works
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lü, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 274 · see citing works
YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches
Piccolo, S., Panciera, T., Contessotto, P., & Cordenonsi, M. (2022) · Nature Cancer · doi:10.1038/s43018-022-00473-z · Cited by 250 · see citing works
The Hippo Pathway in Liver Homeostasis and Pathophysiology
Driskill, J. H., & Pan, D. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-030420-105050 · Cited by 232 · see citing works
Insights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213 · see citing works
Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00577-0 · Cited by 215 · see citing works
Mikubo, M., Inoue, Y., Liu, G., & Tsao, M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.017 · Cited by 212 · see citing works
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 216 · see citing works
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210 · see citing works
Cell–matrix interface regulates dormancy in human colon cancer stem cells
Ohta, Y., Fujii, M., Takahashi, S., Takano, A., Nanki, K., Matano, M., Hanyu, H., Saito, M. K., Shimokawa, M., Nishikori, S., et al. (2022) · Nature · doi:10.1038/s41586-022-05043-y · Cited by 211 · see citing works
Hippo signalling in the liver: role in development, regeneration and disease
Russell, J. O., & Camargo, F. D. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00571-w · Cited by 205 · see citing works
Self-citationEmerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189 · see citing works
Transferrin receptor targeting chimeras for membrane protein degradation
Zhang, D., Duque-Jimenez, J., Facchinetti, F., Brixi, G., Rhee, K., Feng, W. W., Janne, P. A., & Zhou, X. X. (2024) · Nature · doi:10.1038/s41586-024-07947-3 · Cited by 205 · see citing works
MEK inhibitor resistance mechanisms and recent developments in combination trials
Kun, E., Tsang, Y. T. M., Ng, C. W., Gershenson, D. M., & Wong, K. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102137 · Cited by 189 · see citing works
Self-citationDrug-tolerant persister cells in cancer: the cutting edges and future directions
Pu, Y., Li, L., Peng, H., Liu, L., Heymann, D., Robert, C., Vallette, F. M., & Shen, S. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00815-5 · Cited by 179 · see citing works
Apoptosis in Cancer Biology and Therapy
Moyer, A. F., Tanaka, K., & Cheng, E. H. Y. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-115023 · Cited by 201 · see citing works
Nilsson, M. B., Sun, H., Robichaux, J., Pfeifer, M., McDermott, U., Travers, J., Diao, L., Xi, Y., Tong, P., Shen, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4589 · Cited by 177 · see citing works
Pearson, J. D., Huang, K., Pacal, M., McCurdy, S. R., Lü, S., Aubry, A., Yu, T., Wadosky, K. M., Zhang, L., Wang, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.016 · Cited by 172 · see citing works
Li, Y., Chen, H., Xie, X., Yang, B., Wang, X., Zhang, J., Qiao, T., Guan, J., Qiu, Y., Huang, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2370 · Cited by 175 · see citing works
Tanaka, K., Yu, H. A., Yang, S., Han, S., Selçuklu, S. D., Kim, K., Ramani, S., Ganesan, Y. T., Moyer, A. F., Sinha, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.006 · Cited by 165 · see citing works
Self-citationControl of stem cell renewal and fate by YAP and TAZ
Driskill, J. H., & Pan, D. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00644-5 · Cited by 165 · see citing works
Chapeau, E. A., Sansregret, L., Galli, G. G., Chêne, P., Wartmann, M., Mourikis, T. P., Jaaks, P., Baltschukat, S., Barbosa, I. A. M., Bauer, D., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00754-9 · Cited by 163 · see citing works
Therapeutic targeting of TEAD transcription factors in cancer
Pobbati, A. V., Kumar, R., Rubin, B. P., & Hong, W. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.12.005 · Cited by 147 · see citing works
Pharmacological blockade of TEAD–YAP reveals its therapeutic limitation in cancer cells
Sun, Y., Hu, L., Tao, Z., Jarugumilli, G. K., Erb, H., Singh, A., Li, Q., Cotton, J. L., Greninger, P., Egan, R. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34559-0 · Cited by 145 · see citing works
When dormancy fuels tumour relapse
Santos-de-Frutos, K., & Djouder, N. (2021) · Communications Biology · doi:10.1038/s42003-021-02257-0 · Cited by 141 · see citing works
Tao, S., Huang, J., Gao, Y., Li, Z., Wei, Z., Dawes, H., & Guo, S. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.04.031 · Cited by 134 · see citing works
Self-citationHe, J., Qiu, Z., Fan, J., Xie, X., Sheng, Q., & Sui, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01891-4 · Cited by 132 · see citing works
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?
Carpenter, V. J., Saleh, T., & Gewirtz, D. A. (2021) · Cancers · doi:10.3390/cancers13040723 · Cited by 124 · see citing works
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
Zhang, M., Luo, J., Sun, Q., Harber, J., Dawson, A. G., Nakas, A., Busacca, S., Sharkey, A. J., Waller, D. A., Sheaff, M. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21798-w · Cited by 119 · see citing works
Cellular senescence: Neither irreversible nor reversible
Reimann, M., Lee, S., & Schmitt, C. A. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232136 · Cited by 120 · see citing works
de Miguel, F. J., Gentile, C., Feng, W. W., Silva, S. J., Sankar, A., Expósito, F., Cai, W. L., Melnick, M. A., Robles-Oteíza, C., Hinkley, M. M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.005 · Cited by 117 · see citing works
Elamin, Y. Y., Robichaux, J. P., Carter, B. W., Altan, M., Tran, H. T., Gibbons, D. L., Heeke, S., Fossella, F. V., Lam, V. K. L., Le, X., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.006 · Cited by 110 · see citing works
Sun, T., & Chi, J. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.05.004 · Cited by 109 · see citing works
Haderk, F., Chou, Y., Čech, L., Fernández-Méndez, C., Yu, J. X., Olivas, V. R., Meraz, I. M., Rabago, D. B., Kerr, D. L., Gómez, C. F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47423-0 · Cited by 106 · see citing works
Linke, J. A., Munn, L. L., & Jain, R. K. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00745-z · Cited by 107 · see citing works
Reita, D., Pabst, L., Pencreach, E., Guérin, É., Dano, L., Rimelen, V., Voegeli, A., Vallat, L. D., Mascaux, C., & Beau‐Faller, M. (2021) · Cancers · doi:10.3390/cancers13194926 · Cited by 106 · see citing works
Tanaka, Y., Chiwaki, F., Kojima, S., Kawazu, M., Komatsu, M., Ueno, T., Inoue, S., Sekine, S., Matsusaki, K., Matsushita, H., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00240-6 · Cited by 104 · see citing works
A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations
Yamaguchi, H., & Taouk, G. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00928 · Cited by 100 · see citing works
Hypoxia-driven intratumor heterogeneity and immune evasion
Terry, S., Engelsen, A. S. T., Buart, S., El‐Sayed, W., Venkatesh, G. H., & Chouaı̈b, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.004 · Cited by 100 · see citing works
Kashima, Y., Shibahara, D., Suzuki, A., Muto, K., Kobayashi, I. S., Plotnick, D. O., Udagawa, H., Izumi, H., Shibata, Y., Tanaka, K., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2811 · Cited by 101 · see citing works
Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening
Sistigu, A., Musella, M., Galassi, C., Vitale, I., & Maria, R. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02166 · Cited by 98 · see citing works
Gogleva, A. A., Polychronopoulos, D., Pfeifer, M., Poroshin, V., Ughetto, M., Martin, M. J., Thorpe, H., Bornot, A., Smith, P. D., Sidders, B. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29292-7 · Cited by 95 · see citing works
Adachi, Y., Kimura, R., Hirade, K., Yanase, S., Nishioka, Y., Kasuga, N., Yamaguchi, R., & Ebi, H. (2023) · Nature Cancer · doi:10.1038/s43018-023-00575-2 · Cited by 93 · see citing works
Novel insights from a multiomics dissection of the Hayflick limit
Chan, M., Yuan, H., Soifer, I., Maile, T. M., Wang, R. Y., Ireland, A., O'Brien, J. J., Goudeau, J., Chan, L. J., Vijay, T., et al. (2022) · eLife · doi:10.7554/elife.70283 · Cited by 99 · see citing works
“Next, we retrieved a gene set of YAP1/TEAD1 targets assembled by Kurrpa et al. from five separate studies ( Kurppa et al., 2020 ).”
InfluentialChhouri, H., Alexandre, D., & Grumolato, L. (2023) · Cancers · doi:10.3390/cancers15020504 · Cited by 99 · see citing works
Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer
Baroja, I., Kyriakidis, N. C., Halder, G. A., & Moya, I. M. (2024) · Nature Communications · doi:10.1038/s41467-024-46531-1 · Cited by 92 · see citing works
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling
Jeon, H.-M., Kim, J., Cho, H. J., Lee, W. J., Nguyen, D., Kim, S. S., Oh, Y. T., Kim, H., Jung, C., Piñero, G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.007 · Cited by 89 · see citing works
Cell plasticity in cancer cell populations
Shen, S., & Clairambault, J. (2020) · F1000Research · doi:10.12688/f1000research.24803.1 · Cited by 87 · see citing works
Transcription factors in fibroblast plasticity and CAF heterogeneity
Melchionna, R., Trono, P., Carlo, A. D., Modugno, F. D., & Nisticò, P. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02934-4 · Cited by 87 · see citing works
Haikala, H. M., Lopez, T., Köhler, J., Eser, P. O., Xu, M., Zeng, Q., Teceno, T. J., Ngo, K., Zhao, Y., Ivanova, E. V., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2426 · Cited by 85 · see citing works
Self-citationTackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
Blaquier, J. B., Ortiz‐Cuaran, S., Ricciuti, B., Mezquita, L., Cardona, A. F., & Recondo, G. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1912 · Cited by 82 · see citing works
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)
Hsu, P., Yang, C., Jablons, D. M., & You, L. (2020) · Cancers · doi:10.3390/cancers12061361 · Cited by 81 · see citing works
Nie, M., Chen, N., Pang, H., Jiang, T., Jiang, W., Tian, P., Yao, L., Chen, Y., DeBerardinis, R. J., Li, W., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160152 · Cited by 81 · see citing works
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
Yap, T. A., Kwiatkowski, D. J., Dagogo‐Jack, I., Offin, M. D., Zauderer, M. G., Kratzke, R. A., Desai, J., Body, A. L., Millward, M., Tolcher, A. W., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04029-3 · Cited by 81 · see citing works
YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer
Quinn, H. M., Vogel, R., Popp, O., Mertins, P., Lan, L., Messerschmidt, C., Landshammer, A., Lisek, K., Château‐Joubert, S., Marangoni, E., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2801 · Cited by 81 · see citing works
Understanding Drug Sensitivity and Tackling Resistance in Cancer
Tyner, J. W., Haderk, F., Kumaraswamy, A., Baughn, L. B., Ness, B. V., Liu, S., Marathe, H., Alumkal, J. J., Bivona, T. G., Chan, K. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3695 · Cited by 77 · see citing works
Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer
Wiecek, A. J., Cutty, S. J., Kornai, D., Parreno-Centeno, M., Gourmet, L. E., Tagliazucchi, G. M., Jacobson, D. H., Zhang, P., Xiong, L., Bond, G. L., et al. (2023) · Genome biology · doi:10.1186/s13059-023-02963-4 · Cited by 78 · see citing works
Alveolar Differentiation Drives Resistance to <i>KRAS</i> Inhibition in Lung Adenocarcinoma
Li, Z., Zhuang, X., Pan, C.-H., Yan, Y., Thummalapalli, R., Hallin, J., Torborg, S., Singhal, A., Chang, J. C., Manchado, E., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0289 · Cited by 74 · see citing works
Dormant cancer cells: programmed quiescence, senescence, or both?
Truskowski, K., Amend, S. R., & Pienta, K. J. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10073-z · Cited by 76 · see citing works
Brägelmann, J., Lorenz, C., Borchmann, S., Nishii, K., Wegner, J., Meder, L., Ostendorp, J., Ast, D., Heimsoeth, A., Nakasuka, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25728-8 · Cited by 75 · see citing works
Moghal, N., Li, Q., Stewart, E., Navab, R., Mikubo, M., D’Arcangelo, E., Martins-Filho, S. N., Raghavan, V., Pham, N., Li, M., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.12.003 · Cited by 74 · see citing works
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution
Francescangeli, F., Angelis, M. L. D., Rossi, R., Cuccu, A., Giuliani, A., Maria, R. D., & Zeuner, A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10092-4 · Cited by 77 · see citing works
Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine
Barry, E., Simov, V., Valtingojer, I., & Venier, O. (2021) · Cells · doi:10.3390/cells10102715 · Cited by 71 · see citing works
Cellular Dormancy in Cancer: Mechanisms and Potential Targeting Strategies
Min, H.-Y., & Lee, H. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.468 · Cited by 73 · see citing works
Theard, P. L., Sheffels, E., Sealover, N. E., Linke, A. J., Pratico, D. J., & Kortum, R. L. (2020) · eLife · doi:10.7554/elife.58204 · Cited by 69 · see citing works
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
Schade, A. E., Perurena, N., Yang, Y., Rodriguez, C. L., Krishnan, A., Gardner, A., Loi, P., Xu, Y., Nguyen, V. T. M., Mastellone, G. M., et al. (2024) · Nature · doi:10.1038/s41586-024-08031-6 · Cited by 72 · see citing works
Self-citationEGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1
Ando, T., Arang, N., Wang, Z., Costea, D. E., Feng, X., Goto, Y., Izumi, H., Gilardi, M., Ando, K., & Gutkind, J. S. (2021) · Communications Biology · doi:10.1038/s42003-021-02744-4 · Cited by 67 · see citing works
Akkoç, Y., Peker, N., Akçay, A., & Gözüaçık, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627023 · Cited by 69 · see citing works
Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling
Fan, M., Lu, W., Che, J., Kwiatkowski, N. P., Gao, Y., Seo, H.-S., Ficarro, S. B., Gokhale, P. C., Liu, Y., Geffken, E. A., et al. (2022) · eLife · doi:10.7554/elife.78810 · Cited by 68 · see citing works
Self-citationTargeting the Hippo pathway in cancer
Harvey, K. F., & Tang, T. T.-L. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01234-0 · Cited by 64 · see citing works
Zhao, J., Xu, W., Zhou, F., Zhang, X., Zhou, M., Miao, D., Yu, L., Zhang, Y., Fan, J., Zhou, C., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01085-z · Cited by 66 · see citing works
Context-dependent roles of YAP/TAZ in stem cell fates and cancer
LeBlanc, L., Ramirez, N., & Kim, J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03781-2 · Cited by 63 · see citing works
Noia, V. D., D’Aveni, A., D’Argento, E., Rossi, S., Ghirardelli, P., Bortolotti, L., Vavassori, V., Bria, E., & Ceresoli, G. L. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100280 · Cited by 60 · see citing works
New Insights into YAP/TAZ-TEAD-Mediated Gene Regulation and Biological Processes in Cancer
Zhao, Y., Sheldon, M., Sun, Y., & Ma, L. (2023) · Cancers · doi:10.3390/cancers15235497 · Cited by 59 · see citing works
Stewart, C. A., Gay, C. M., Ramkumar, K., Cargill, K. R., Cardnell, R. J., Nilsson, M. B., Heeke, S., Park, E. M., Kundu, S. T., Diao, L., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.002 · Cited by 84 · see citing works
Criscione, S. W., Martin, M. J., Oien, D. B., Gorthi, A., Miragaia, R. J., Zhang, J., Chen, H., Karl, D. L., Mendler, K., Markovets, A. A., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00337-w · Cited by 55 · see citing works
Targeted therapy and drug resistance in thyroid cancer
Zhang, Y., Xing, Z., Liu, T., Tang, M., Mi, L., Zhu, J., Wu, W., & Wei, T. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114500 · Cited by 55 · see citing works
Chen, R., Qian, Z., Xu, X., Zhang, C., Niu, Y., Wang, Z., Sun, J., Zhang, X., & Yu, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105442 · Cited by 53 · see citing works
Liu, S., Jiang, A., Tang, F., Duan, M., & Li, B. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02323-9 · Cited by 53 · see citing works
Wang, Y., Liu, L., Song, Y., Yu, X., & Deng, H. (2022) · Protein & Cell · doi:10.1007/s13238-021-00894-z · Cited by 52 · see citing works
Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors
Lu, W., Fan, M., Ji, W., Tse, J., You, I., Ficarro, S. B., Tavares, I., Che, J., Kim, A. Y., Zhu, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01548 · Cited by 52 · see citing works
Self-citationProtein-Protein Interaction Disruptors of the YAP/TAZ-TEAD Transcriptional Complex
Pobbati, A. V., & Rubin, B. P. (2020) · Molecules · doi:10.3390/molecules25246001 · Cited by 52 · see citing works
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)
Zagiel, B., Melnyk, P., & Cotelle, P. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2096436 · Cited by 51 · see citing works
Biomolecular condensates: hubs of Hippo-YAP/TAZ signaling in cancer
Kiang, K. M. Y., Ahad, L., Zhong, X., & Lu, Q. R. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.04.009 · Cited by 50 · see citing works
Targeting Hippo signaling in cancer: novel perspectives and therapeutic potential
Lv, L., & Zhou, X. (2023) · MedComm · doi:10.1002/mco2.375 · Cited by 47 · see citing works
Alsaed, B., Lin, L., Son, J., Li, J., Smolander, J., Lopez, T., Eser, P. Ö., Ogino, A., Ambrogio, C., Eum, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55378-5 · Cited by 50 · see citing works
Self-citationThinking Differently about Cancer Treatment Regimens
Settleman, J., Neto, J. M. F., & Bernards, R. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1187 · Cited by 48 · see citing works
Liu, W., Jin, W., Zhu, S., Chen, Y., & Liu, B. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.10.011 · Cited by 48 · see citing works
Hippo Signaling at the Hallmarks of Cancer and Drug Resistance
Kumar, R., & Hong, W. (2024) · Cells · doi:10.3390/cells13070564 · Cited by 47 · see citing works
GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling
Li, X., Wang, H., Yang, X., Wang, X., Zhao, L., Zou, L., Yang, Q., Hou, Z., Tan, J., Zhang, H., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.028 · Cited by 47 · see citing works
Self-citationThe Hallmarks of Cancer as Ecologically Driven Phenotypes
Somarelli, J. A. (2021) · Frontiers in Ecology and Evolution · doi:10.3389/fevo.2021.661583 · Cited by 46 · see citing works
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
Rosell, R., Cardona, A. F., Arrieta, O. G., Aguilar, A., Ito, M., Pedraz‐Valdunciel, C., Codony‐Servat, J., & Santarpía, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01519-2 · Cited by 46 · see citing works
Hu, L., Sun, Y., Liu, S., Erb, H., Singh, A., Mao, J., Luo, X., & Wu, X. (2022) · eLife · doi:10.7554/elife.80210 · Cited by 48 · see citing works
Role Of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer
Zhou, W., Lim, A., Edderkaoui, M., Osipov, A., Wu, H., Wang, Q., & Pandol, S. J. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83586 · Cited by 43 · see citing works
Pfeifer, M., Brammeld, J. S., Price, S., Pilling, J. E., Bhavsar, D., Farcas, A. M., Bateson, J., Sundarrajan, A., Miragaia, R. J., Guan, N., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06190-w · Cited by 43 · see citing works
Mechanosensitive genomic enhancers potentiate the cellular response to matrix stiffness
Cosgrove, B. D., Bounds, L. R., Taylor, C. K., Su, A. L., Rizzo, A. J., Barrera, A., Sun, T., Safi, A., Song, L.-Y., Whitlow, T., et al. (2025) · Science · doi:10.1126/science.adl1988 · Cited by 26 · see citing works
- Authors
- Kurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., Portell, A., Lizotte, P. H., Ficarro, S. B., Li, S., Chen, T., Haikala, H. M., Wang, H., Bahcall, M., Gao, Y., Shalhout, S., Boettcher, S., Shin, B. H., Thai, T., Wilkens, M. K., Tillgren, M. L., Mushajiang, M., Xu, M., Choi, J., Bertram, A. A., Ebert, B. L., Beroukhim, R., Bandopadhayay, P., Awad, M. M., Gokhale, P. C., Kirschmeier, P. T., Marto, J. A., Camargo, F. D., Haq, R., Paweletz, C. P., Wong, K.-K., Barbie, D. A., Long, H. W., Gray, N. S., & Jänne, P. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- NYU Langone Health (US)
- Tongji University (CN)
- Boston Children's Hospital (US)
- Broad Institute (US)
- ORCID
- Kurppa, Kari J.
- Liu, Yao
- To, Ciric
- Zhang, Tinghu
- Fan, Mengyang
- Vajdi, Amir
- Knelson, Erik H.
- Xie, Yingtian
- Lim, Klothilda
- Cejas, Paloma
- Portell, Andrew
- Lizotte, Patrick H.
- Ficarro, Scott B.
- Li, Shuai
- Chen, Ting
- Haikala, Heidi M.
- Wang, Haiyun
- Bahcall, Magda
- Gao, Yang
- Shalhout, Sophia
- Boettcher, Steffen
- Shin, Bo Hee
- Thai, Tran
- Wilkens, Margaret K.
- Xu, Man
- Choi, Jihyun
- Bertram, Arrien A.
- Ebert, Benjamin L.
- Beroukhim, Rameen
- Bandopadhayay, Pratiti
- Awad, Mark M.
- Gokhale, Prafulla C.
- Marto, Jarrod A.
- Camargo, Fernando D.
- Haq, Rizwan
- Paweletz, Cloud P.
- Wong, Kwok-Kin
- Barbie, David A.
- Long, Henry W.
- Gray, Nathanael S.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 37
- Issue
- 1
- Pages
- 104-122.e12
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC7146079
- OpenAlex
- W3000285141
- Cited by
- 475
- References
- 92
- Citations by year
- 2026: 50 · 2025: 94 · 2024: 82 · 2023: 81 · 2022: 71 · 2021: 65 · 2020: 30
- FWCI
- 30.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UTUPub (University of Turku) (submittedVersion)
- Funders
- National Cancer Institute (NIH 5 P30 CA06516, R01CA135257, R35CA220497)
- Novartis Institutes for BioMedical Research
- Bristol-Myers Squibb
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Eli Lilly and Company
- Daiichi Sankyo Company
- Astellas Pharma US
- Dana-Farber/Harvard Cancer Center
- American Cancer Society (CRP-17-111-01-CDD)
- Takeda Oncology
- Massachusetts Institute of Technology
- Instrumentariumin Tiedesäätiö
- Takeda Pharmaceuticals U.S.A.
- National Science Foundation (P300PB_161026/1, P400PM_183862)
- Dana-Farber Cancer Institute
- National Institutes of Health (CA233800, R01 CA222218)
- Jane ja Aatos Erkon Säätiö
- Novartis
- Krebsliga Schweiz (KLS-3625-02 2015)
- Sanofi
- Orionin Tutkimussäätiö
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- tumor dormancy, EGFR tyrosine kinase inhibitors, EGFR-mutant non-small cell lung cancer, MEK inhibition, Slug, BMF, apoptosis, transcriptional reprogramming, drug resistance
- MeSH terms
- YAP-Signaling Proteins, Animals, Cell Survival, Female, Humans, Lung Neoplasms, Male, Mutation, Transcription Factors, Transcription, Genetic, Signal Transduction, Gene Expression Regulation, Neoplastic, Cellular Senescence, Apoptosis, Gene Deletion, Mice, Knockout, Cell Cycle Proteins, Drug Resistance, Neoplasm, Cell Line, Tumor, MAP Kinase Kinase 1, Adaptor Proteins, Signal Transducing, Cell Proliferation, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
